A Phase I-IIa Trial on the Safety and Preliminary Effectiveness of Intramyocardial Injection of Cardiac Atrial Stem Cells for the Treatment of Advanced Ischemic Heart Failure in Subjects with Ischemic Left Ventricular Dysfunction and Chronic Myocardial Infarction.

Conditions

Heart Failure

Brief summary

MACE : • Death and cause of death, MACE : • Re-admissions and cause of re-admission, MACE : • Myocardial infarction, MACE : • Tumour formation

Detailed description

safety - non-MACE : • worsening of heart failure events defined as requiring unscheduled treatment for signs and symptoms of heart failure in an urgent outpatient setting or requiring hospital admission, safety - non - MACE: • aborted sudden death events, defined as resuscitated sudden death or appropriate Automatic Implantable Cardioverter Defibrillator (AICD) therapy for severe ventricular tachyarrhythmias, safety - non-MACE : • change in Six-Minute Walk Test from pre-procedure, safety - non-safety : • total days alive out of hospital, safety - non - MACE : • changes in NYHA class from pre-procedure and proportion of patients with improved NYHA classification, efficacy : • global and regional left ventricular function, efficacy : • ventricular dimensions, efficacy : • measurements of infarct size

Related papers

No related papers found yet.

Interventions

DRUGCardiac atrial stem cells

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
MACE : • Death and cause of death, MACE : • Re-admissions and cause of re-admission, MACE : • Myocardial infarction, MACE : • Tumour formation	—

Secondary

Measure	Time frame
safety - non-MACE : • worsening of heart failure events defined as requiring unscheduled treatment for signs and symptoms of heart failure in an urgent outpatient setting or requiring hospital admission, safety - non - MACE: • aborted sudden death events, defined as resuscitated sudden death or appropriate Automatic Implantable Cardioverter Defibrillator (AICD) therapy for severe ventricular tachyarrhythmias, safety - non-MACE : • change in Six-Minute Walk Test from pre-procedure, safety - non-safety : • total days alive out of hospital, safety - non - MACE : • changes in NYHA class from pre-procedure and proportion of patients with improved NYHA classification, efficacy : • global and regional left ventricular function, efficacy : • ventricular dimensions, efficacy : • measurements of infarct size	—

Measure

Time frame

safety - non-MACE : • worsening of heart failure events defined as requiring unscheduled treatment for signs and symptoms of heart failure in an urgent outpatient setting or requiring hospital admission, safety - non - MACE: • aborted sudden death events, defined as resuscitated sudden death or appropriate Automatic Implantable Cardioverter Defibrillator (AICD) therapy for severe ventricular tachyarrhythmias, safety - non-MACE : • change in Six-Minute Walk Test from pre-procedure, safety - non-safety : • total days alive out of hospital, safety - non - MACE : • changes in NYHA class from pre-procedure and proportion of patients with improved NYHA classification, efficacy : • global and regional left ventricular function, efficacy : • ventricular dimensions, efficacy : • measurements of infarct size

—

Countries

Belgium

Outcome results

None listed